Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...

35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...

"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.

Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...